Free Trial

HLS Therapeutics Q1 2023 Earnings Report

HLS Therapeutics logo
C$4.17 -0.02 (-0.48%)
As of 02/21/2025 03:39 PM Eastern

HLS Therapeutics EPS Results

Actual EPS
-C$0.24
Consensus EPS
-C$0.16
Beat/Miss
Missed by -C$0.08
One Year Ago EPS
N/A

HLS Therapeutics Revenue Results

Actual Revenue
$19.96 million
Expected Revenue
$21.26 million
Beat/Miss
Missed by -$1.30 million
YoY Revenue Growth
N/A

HLS Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

HLS Therapeutics Earnings Headlines

Top Canadian Pharmaceutical Stocks of 2025
Optimistic Buy Rating for HLS Therapeutics Despite Revenue Challenges
The Real Hillbilly Elegy
The mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky, Tennessee and beyond… It's one of our country’s most scenic areas. But hidden beneath the beauty is an ugly reality: our most beautiful land is also the poorest. It’s a tragedy because for over 200 years, generation after generation has worked “coal country” with nothing but a pick and shovel, hauling billions of dollars from the ground.
See More HLS Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email.

About HLS Therapeutics

HLS Therapeutics (TSE:HLS), a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

View HLS Therapeutics Profile

More Earnings Resources from MarketBeat